Join to View Full Profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3466
Fax+1 617-632-2165
Dr. Xu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Wenxin Xu is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. He received his medical degree from Harvard Medical School and completed residency and fellowship training at Beth Israel Deaconess Medical Center. He specializes in genitourinary oncology.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2014 - 2017
Harvard Medical SchoolClass of 2014
Certifications & Licensure
NH State Medical License 2022 - 2026
MA State Medical License 2018 - 2025
ME State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award Conquer Cancer Foundation, 2020
Publications & Presentations
PubMed
- KIM-1 as a Prognostic Marker in Renal Cell Carcinoma.Clara Steiner, Marc Machaalani, Joseph V Bonventre, David F McDermott, Toni K Choueiri
European Urology Focus. 2025-07-05 - Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.Chris Labaki, Eddy Saad, Katrine N Madsen, Charbel Hobeika, Kevin Bi
Journal of Clinical Oncology. 2025-07-02 - Spinal Instability Neoplastic Score as a Predictor of Vertebral Fracture in Patients Undergoing Radiation Therapy for Spinal Metastases: A Single-Institution Study.Patrick Doyle, Sarah Caplan, Neil Klinger, Kee-Young Shin, Michael Groff
Advances in Radiation Oncology. 2025-07-01
Press Mentions
Dana-Farber Researchers Present Findings at 2025 ASCO Genitourinary Cancers SymposiumFebruary 11th, 2025- OncoHost Announces New Study on Biomarkers for Renal Cell CarcinomaJune 3rd, 2024
- Dana-Farber Cancer Institute and OncoHost Partner for Renal Cell Carcinoma ResearchJune 13th, 2024
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
